Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects

OBJECTIVE: The development of new insulin sensitizers is an unmet need for the treatment of type 2 diabetes. We investigated the effect of GFT505, a dual peroxisome proliferator–activated receptor (PPAR)-α/δ agonist, on peripheral and hepatic insulin sensitivity. RESEARCH DESIGN AND METHODS: Twenty-...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Cariou, Bertrand, Hanf, Rémy, Lambert-Porcheron, Stéphanie, Zaïr, Yassine, Sauvinet, Valérie, Noël, Benoit, Flet, Laurent, Vidal, Hubert, Staels, Bart, Laville, Martine
Format: Artigo
Jezik:Inglês
Izdano: American Diabetes Association 2013
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3781493/
https://ncbi.nlm.nih.gov/pubmed/23715754
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc12-2012
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items